Biosimilars in the Pharmacy Benefit
Action Brief (Jun. 2020)

Uptake on many biosimilars has been slow, in part because employers are often unsure about how to take appropriate action to encourage more – and more affordable – pharmaceutical options for employees and their dependents. Biosimilars in the Pharmacy Benefit Action Brief – 06 2020
This content is only available to members. Learn more about membership here or login.